HIBT Lab! Immunai: Noam Solomon

According to the CDC, 6 in 10 adults in the U. S. have a chronic disease like cancer or diabetes. Meanwhile, the process for discovering new drug treatments is critically expensive and inefficient. About 90% of drug candidates fail to gain FDA approval; the average cost to develop a new drug is over $1 billion; and testing can take over 10 years. Noam Solomon is on a mission to change this. His company, Immunai, is using artificial intelligence to create an atlas of the human immune system. This week on How I Built This Lab, Guy talks with Noam about how Immunai’s immune system mapping is accelerating the development of new personalized drug therapies. Plus, Noam shares how Immunai’s culture of ‘not knowing’ drives scientific innovation. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Speaker names marked ? are inferred from speaking time and the show’s known hosts — they are not voice-verified.

• 0:00Guy Raz?

  Our presenting sponsor today is Anthropic, the team behind Claude. Every founder on this show started with a hard question. Not the marketing plan, the 2 a.m. kind. Is this idea any good? Am I the one to build it? Should I quit my job? Anthropic got built the same way. A public benefit corporation founded on one hard question. How do we make sure AI goes well for people? So they asked over 100,000 people their hopes and their fears and are publishing what they find, even the uncomfortable parts. Me? I've got my own hard question about AI. Here it is. If everyone has access to something that can help them write the business plan,

• 0:46Guy Raz?

  build the prototype, analyze the market, maybe even come up with the idea, what separates the people who actually build something from everyone else? I don't have a clean answer yet, so I've been sitting with it with Claude. There's hope in hard questions. Ask yours at claude.ai/hibt. We get support from U.S. Bank. A question I love asking founders. What's the one decision you almost didn't make? The one that changed everything? Because it's never the obvious stuff. It's never, I decided to start a company. It's the small, boring, Tuesday afternoon decision you barely remember making until you realize it's the reason everything after it either worked or didn't.

• 1:32Guy Raz?

  Say you're 18 months in. Business is growing. You've got expenses coming from six directions. Gas for the van, office supplies, your phone bill, team lunches that are actually client meetings, and you're putting it all on whatever card you grabbed in year one. You're not thinking about it. Why would you? You've got bigger problems. But here's the thing. Path A, you keep going like that. End of the year, you're sorting through statements, trying to figure out what went where. You've left hundreds, maybe thousands on the table in rewards you never earned, money that could have gone back into the business. Path B, you pause and get The US Bank Triple Cash Rewards Visa Business Card.

• 2:14Guy Raz?

  Now you're earning 3% cash back on gas and EV charging, office supply stores, cellphone service, and restaurants. You pick up an extra $750 cash back as a bonus. And you've got a low APR on purchases and balance transfers for 12 months while you're scaling. Same business, same expenses, two completely different outcomes based on one small decision. Visit usbank.com/business to learn more. The creditor and issuer of this card is US Bank National Association pursuant to a license from Visa USA Inc. Some restrictions apply. If you travel often, you'll want to hear about this unprecedented offer.

• 2:58Guy Raz?

  For the first time ever, new Delta SkyMiles Reserve American Express Card members can earn two Delta Comfort round trip flights for travel within the 48 contiguous US states, Puerto Rico, or the US Virgin Islands. Plus, you can earn 50,000 bonus miles towards your next getaway. And who doesn't appreciate an elevated airport experience? Delta SkyMiles Reserve Card members get access to the Delta Sky Club, your pre-flight oasis to recharge with 15 visits and four one-time guest passes each medallion year when flying Delta together. That's up to $950 in annual value.

• 3:40Guy Raz?

  Value estimate based on $50 per visit rate to purchase additional visits or bring a guest to the Delta Sky Club. Make every trip feel more rewarding with the card that upgrades your travel. Apply today at delta.com/cardsocial. Offer ends November 4, 2026. Minimum spending requirements and terms apply. Flights are fulfilled as flight certificates valid for Delta Comfort or Delta Maine to select domestic destinations. Book 21-plus days in advance. Up to $80 per person and taxes and fees apply. Other restrictions apply. When I pull up to a gas pump to fill my car, I'm not thinking about chemistry or engineering. I'm thinking about getting in, filling up, and getting on with my day.

• 4:23Guy Raz?

  And it reminds me a little bit of the founders I talked to on this show, because the best ones obsess over things their customers will never see. Tiny details, invisible improvements, relentless iteration. And not because anyone's watching, but because it makes the product better. That's what the mobile brand does. It engineers fuel the same way great founders engineer their products. Mobile Supreme Plus Premium Gas helps keep engines three times cleaner, which can mean better performance and improved gas mileage. It's for people who care about what's under the hood, even if they never see it. Three times cleaner compared to mobile regular gas in port-fuel-injected engines. Actual results may vary.

• 5:07Guy Raz?

  Visit mobili fuels.com for details.

• 5:13Guy Raz?

  Hello and welcome to How I Built This Lab. I'm Guy Raz. So if we've learned anything from our experience with COVID over the past few years, it's that we still have a lot to learn about how the human body fends off and fights disease. My guest today is on a mission to change that. In 2018, Noam Solomon and his co-founders launched a company called Immunai, and it's working to create what's essentially an atlas of the human immune system. There are thousands of clinical trials that take place each year around the world where people with certain diseases and conditions are given experimental medicine. Immunai partners with hospitals and universities to gather cellular-level data from those clinical trials.

• 5:57Guy Raz?

  The company's massive computing power and artificial intelligence programs then analyze that data, which can then help figure out which experimental treatments work and which ones don't. Noam believes that eventually, immunized technology can help pharmaceutical companies develop more effective treatments for some of the most serious diseases, including cancers. Immunai has offices in New York, Tel Aviv, and in Europe, and it's raised over $200 million for this work. Between them, immunized founders have backgrounds in computer science, advanced mathematics, and biology. Noam, the CEO, joined me from his office in Tel Aviv.

• 6:37Speaker 01

  So I knew I was going to be an academic even before I was 10 years old. And the plan was to be a faculty member and doing research in math and computer science. And I have a change of plans.

• 6:52Guy Raz?

  From what I gather, you ended up in the United States around 2017. You came here to do some postdoc work in mathematics and computer science at Harvard. And then you went on to MIT to do more postdoc work in mathematics. And that's really kind of where your, I guess, your career path was like derailed, in a good way, because you did not go in the direction of mathematics and computer science. Tell me what happened. What started the idea that would eventually become Immunai?

• 7:23Speaker 01

  So about five years before then, for my second PhD, I wanted to have some additional income. So I worked in a few startup companies as a data scientist and developed some algorithms in different disciplines and fields. It was not in biology. So e-commerce, ad tech, different types of web applications. And it was mainly to supplement the income. Working as an academic, especially in Israel, it's a challenge. A few years later, for my postdoc, my co-founder and CTO at the time, we met as friends. He told me about his grandfather.

• 8:08Speaker 01

  At the time, he had cancer. He was getting a combination of immunotherapies, and it was working for him. So the cancer was regressing, but he couldn't stand the side effects, the adverse events. So he stopped taking the medication. So eventually, a couple of years later, the grandfather died. At the time, I was very, very interested to understand if you could use data science and mathematics to better find the right therapy for the patient. So this was a starting point for me, whether you can use some of the knowledge and background that I have to maybe do something that can impact patients.

• 8:48Guy Raz?

  What was the opportunity you saw that you could contribute to in developing technology that could really transform medicine?

• 8:55Speaker 01

  Yeah, so it's a deep question. Immunotherapies, like the name, are drugs that are targeting our immune system. Our immune system is an incredibly complex system that is essentially governing our health, the way that we respond to therapeutics, the way that we cope with different bacteria and viruses. Of course, the entire world now understands, after the few years that we had with COVID, how important the immune system really is. But how can you know if a patient is going to respond to an immunotherapy or not? And maybe one patient is going to respond to a drug and another patient is not going

• 9:37Speaker 01

  to respond to the drug, and you personalize the treatment. So this was the starting point for us. How can you create the knowledge base to answer this question?

• 9:48Guy Raz?

  You've described Immunize work as sort of like creating a Google Maps of the human immune system, right, more or less?

• 9:57Speaker 01

  Yeah.

• 9:58Guy Raz?

  So what does mapping the human immune system mean?

• 10:01Speaker 01

  Right, so the different cells in our body, we have trillions and trillions of cells, they are different. You have cells within your immune system, within the different organs, and what is important is first to understand the makeup of our cells, but also the way that they interact with one another. So let's say somebody is being exposed to a virus or a drug. It's not going to be one cell, it's going to be many cells being impacted by this. How do you measure on a system level the way that cells interact with one another? So this is the type of challenge that I don't think we were able to cope with five or 10 years ago. But I think the increase of technologies, for example, single-cell technologies, allow

• 10:46Speaker 01

  us to measure cells.

• 10:50Speaker 01

  Individually, so we can map every single cell separately. Every cell is giving you the ability to look at twenty thousand different genes. And then you can look at hundreds of different proteins. You can look at many, many different characteristics and variables. So for example, we are going to generate one terabyte of information from every sample that we take from a patient. So it's a massive amount of data that we generate. And then we are trying to make sense of this data. But the reason why I called it Google Maps is because we also want to help people get from where they are today. Sometimes it's a it's a state or city of disease and they want to go to a state or city of cure.

• 11:36Speaker 01

  How do you find the the way there? And this is where the mapping of the human immune system is a means to an end. And the end is to find novel therapies that can help patients get to where they are trying to get.

• 11:50Guy Raz?

  Noam, has the the sort of the absence of a map or maps of the human immune system essentially held science, scientists back, researchers back from developing effective treatments for, you know, for a variety of diseases?

• 12:06Speaker 01

  Yes, I think today the way that medicine is being discovered and developed is based on a trial and error of scientists in the lab. Having a map of the human immune system will enable researchers to apply data mining tools to come up with novel ways to develop and discover therapeutics.

• 12:26Guy Raz?

  What's been the biggest challenge in in? I mean, why hasn't the human immune system been mapped? What's what's been the technological obstacle that has prevented that from happening until now?

• 12:38Speaker 01

  I think technology is changing very rapidly. What happened in the in the past five years was, in some sense, a perfect storm where compute power has grown dramatically.

• 12:49Speaker 01

  We have seen more and more, and we keep seeing more and more technologies in biology, in chemistry, that allow us to measure things in, you know, unprecedented resolution granularity. And we have more sophisticated algorithms. So I think this perfect storm of technology and science allows us to do things we couldn't have even dreamed like fifteen and twenty years ago.

• 13:13Guy Raz?

  Yeah, right. My assumption is every single human has a somewhat different immune system. Our immune responses vary widely from human to human. And essentially, if you mapped the human immune system and everybody had access to this mapping, you could develop personalized treatments more quickly.

• 13:30Speaker 01

  It is true. And similarly, I think that, you know, the colors of our eyes are slightly different, but there are categories. And I think that when you map thousands of people, of patients, and you will find a lot of similarities. So I think the similarities allow us and make us confident that we could measure the human immune system and try to understand how patients that have breast cancer or non-small cell lung cancer, open pancreatic cancer can be clustered into groups. And those immune systems profiles will allow us to figure out what will be the right therapy for them.

• 14:11Speaker 01

  I believe that the world is going into a more personalized way to understand our health. And I really hope that medicine is going to go into preventive care and not only into medical care, right? I mean, when you're very tired in the past few months, maybe there is an immune reason for that. So when we understand the immune system better and better, and we map more areas of the immune system, we will be able to cope with more rare autoimmune indications, orphan disease and other, you know, cancer indications that only few patients have. And, you know, there are certain indications that are not getting enough funding because not enough patients have them.

• 14:54Speaker 01

  The vision that I have and the hope that I have is that maybe in fifteen years, we'll be able to use our immune profiling capabilities to help people remain healthy.

• 15:03Guy Raz?

  Hmm. So Noam, can you sort of lay out what the challenges right now are with developing immunotherapy treatments?

• 15:12Speaker 01

  So first of all, drug development is becoming increasingly inefficient.

• 15:18Speaker 01

  It is super expensive. So to develop a new immunotherapy takes more than $2.6 billion. It takes more than 10 years of research and development before market. And more than 90% of drugs fail to get an FDA approval.

• 15:34Guy Raz?

  All right. So it's a massive investment of money in something that is uncertain. So basically, I'm assuming that when pharmaceutical companies take a swing like that, they have to be pretty sure that there's a good chance it could work before they're going to put $2.5 billion into something.

• 15:49Speaker 01

  Right.

• 15:50Guy Raz?

  And so essentially, what you're saying is if we can begin to map the human immune system with increasing granularity, you could start to solve some of these development and research challenges?

• 16:05Speaker 01

  So I will tell you something that a great scientist told me as we were starting. He said, "We can cure every type of cancer in mice."

• 16:17Speaker 01

  And this really gave me a pause, and I've been thinking about this for years. Understanding how to bridge the gap between the human immune response and the way that drugs are being tested in animal models is, I believe, the biggest challenge that the biopharma and biotechnology industry should face and will face in the coming decade or two. And this is our vision. Our vision is to improve the drug development process through an engineering-first mapping of the human immune system and through the human immune response.

• 16:51Guy Raz?

  We're going to take a quick break, but when we come back, more from Noam Solomon on how his company, Immunai, is using artificial intelligence in the fight against cancer and other diseases. Stay with us. I'm Guy Raz, and you're listening to How I Built This Lab.

• 17:10Guy Raz?

  Does your team want a website that looks and feels handcrafted but is still fast to ship? Well, Framer is built exactly for that. With Framer, you design on a visual canvas with responsive layouts, hosting, and a CMS built in, so the work is Production ready from day one, and you can get it done with help from Framer's AI agents. Framer is the AI website builder that helps creators, teams, and businesses ship production-ready sites faster than ever while getting every detail right. Prompt, inspect, edit, and publish in one place at a whole new pace. AI agents and humans work together. The agents bring speed and scale,

• 17:54Guy Raz?

  and people bring taste, judgment, and control. Learn how you can get more out of your site from a Framer specialist or get started building for free today at framer.com/built for 30% off a Framer Pro annual plan. That's framer.com/built. Rules and restrictions may apply. AI isn't just opening new business opportunities, it's changing the way businesses get work done. The questions they ask, the decisions they make, the routine tasks they can hand off. That's the idea behind NetSuite Next, the next generation of NetSuite with AI woven into the tools your business already relies on.

• 18:37Guy Raz?

  NetSuite Next surfaces insights exactly when you need them, puts agents to work on routine tasks and problems, and lets you ask complex questions in plain language, like talking to a knowledgeable colleague. But technology is only part of the story. AI is also reshaping how people and teams work together, and that shift is already underway. That's why NetSuite wants to put a new expert-created business guide in your hands today. It's called Aligning for the Agentic Era: How AI is Changing Everyday Work. And right now, it's yours, absolutely free. Inside, you'll discover how AI could reshape work across your entire organization and how to position your business to prosper from it.

• 19:22Guy Raz?

  If your revenues are at least in the seven figures, get NetSuite's free business guide, Aligning for the Agentic Era: How AI is Changing Everyday Work, at netsuite.com/built. The guide is free to you at netsuite.com/built. netsuite.com/built.

• 19:41Guy Raz?

  Stripe is built for whatever comes next because the pace of change has never been faster than it is right now. New business models, new currencies, and new expectations for speed, reliability, and scale. Stripe builds financial infrastructure that helps businesses start, grow, and operate globally. From payments and billing to fraud protection and cross-border payouts, Stripe is built to support the new pace of commerce. They're trusted by the companies building at the frontier, from 86% of the Forbes AI 50 to global leaders like Salesforce and OpenAI.

• 20:20Guy Raz?

  In fact, more than 1.6% of global GDP flows through Stripe, with Stripe's users processing a combined $1.9 trillion last year. So if you're already thinking about what's next for your business, see what's possible at stripe.com.

• 20:46Guy Raz?

  Welcome back to How I Built This Lab. I'm Guy Raz, and my guest today is Noam Solomon, whose company is combining data science and biology to develop more effective treatments for all sorts of medical conditions. You know, I want to ask you about the business side of this for a moment because this is a business that you're building. You've raised almost $300 million, and that's not enough, right? I mean, I'm assuming that the research and staffing costs are incredibly high. So, I mean, how much money do you think this will take?

• 21:17Speaker 01

  So, there are a few aspects to the business here. First is that we are already working and making money by working with our partnerships. You know, large biopharma companies are paying us good money to help them further develop and improve the development of their drug candidates and other drugs.

• 21:35Guy Raz?

  They're paying for your data and your insights?

• 21:38Speaker 01

  They're paying us for, not only for data and insights, but for generating the data on their samples and gleaning insights that are going to improve the clinical trial design and the chance for getting their drugs approved in the clinic. So this is already something that we are doing, and the nice thing about it is that our machine intelligence keeps getting better and better and better. The other aspect is the core vision and the mission statement of the company is about building something unique and differentiated, and it is super risky. So our premise is that we are going to map the human immune system, but that the implications

• 22:21Speaker 01

  of this is going to make a real dent in the way that we discover and develop therapeutics. And, you know, it's been four years, we have had a lot of progress and successes, but the risk is still here with us. And I think that everybody that joined Immunai and our investor that invested a lot of money, they understand that this is still a very ambitious scientific project.

• 22:48Guy Raz?

  Yeah, I mean, you're and you're not the only company out there that is doing this work. Do you see the other companies as competitors or as potential collaborators, as both maybe?

• 22:58Speaker 01

  So first, I really like competition. I think there are many competitive companies in our landscape, and I think some companies are, you know, really making progress, and for that I congratulate them, and I think it's good for all of us. I think that at the end of the day, companies that are building real technology and real science will succeed, and I think that we are working with some of the more ambitious ones. We are very collaborative in our premise. We have over thirty partnerships, some of them are with companies such as ourselves, earlier stage companies that are building new technologies, some of them are more mature than us.

• 23:38Speaker 01

  But I believe that every company that is able to, you know, bring a scientific vision that is real and make progress towards an important problem will survive. I always say, ladies' science has to dance with us. We have to prove our premise. We have to show that mapping the human immune system can lead to a real ability to improve patients' outcome and improve the clinical trial design. So the collaboration is part of, I believe, the new drug development paradigm shift.

• 24:17Guy Raz?

  What does it mean for the kind of insights that you're able to provide to pharmaceutical companies and companies that are developing these therapeutics?

• 24:23Speaker 01

  So take a drug candidate. Some biopharma or biotechnology company invested a lot of money in this drug candidate. There was an FDA approval to start giving this drug as a clinical trial setup to the patients and you start treating patients that have serious disease. What we are able to do is measure the human immune response of the patients and try to see whether this immune response resembles something which is good, that is effective. And we do it in a way that allows you to leverage the entire power of the database and only a handful of patient samples from the clinical trial.

• 25:07Speaker 01

  This is kind of the secret. So you have a huge database on the backend and then you can use this huge database to glean insights by looking at only a handful of patients in a clinical trial setup.

• 25:19Guy Raz?

  Help me understand what you're doing. Essentially, are you collecting blood samples from patients all around the world? I mean, how do you actually collect the data?

• 25:28Speaker 01

  So there are a few ways. We have many partnerships with academic centers and biopharma and biotechnology companies and every one of our partners are sending samples to us. The samples can be blood samples, they can be preserved immune cells from tissues, from solid tissues, from bone marrow. And our work is to try and create the human immune profile of the patients from the different sources of tissues and blood that we are getting. The more partnerships we have, the more biological samples that we get. And every one of the biological samples that are getting to our lab in New York is being

• 26:10Speaker 01

  profiled and sequenced in our lab and this data is being uploaded to our database, which is called AMICA. It is the largest of its kind database of the immune system with a single cell resolution. So today, we have a database that spans over 100,000 patients, over 500 different disease indications, thousands of studies, and we're trying to put as much clinical context and clinical metadata into the patients. And the more data that we have, the better our mapping of the human immune system is.

• 26:43Guy Raz?

  So I understand that in recently that you've been able to show sort of definitively that there are certain treatments that have improved patient outcomes in certain cases. Can you tell me about that?

• 26:55Speaker 01

  Yeah, so a lot of our work with our partners is to help them with their clinical development. So they have a drug, a drug candidate in clinical trials, and they do a lot of experiments. So they usually have multiple clinical arms. They're trying different combinations of treatments. And we were able to show quite definitively that our platform can identify the preferred combination arm that will demonstrate a superior immune response. So it happened already, and it's something that gets both us and our partners very excited about, the potential to really leverage this immune profiling capability.

• 27:36Guy Raz?

  Okay, help me understand how you can develop treatments and the types of treatments you might develop from what you're building now?

• 27:46Speaker 01

  Yeah, I'll give you a couple of examples. So first of all, when there already are immunotherapies that are being in the clinic treating patients, and for cancer indications like melanoma and non-small cell lung cancer, we see how effective they are. But even in the most effective setups, they don't cure 100% of patients.

• 28:10Guy Raz?

  Right.

• 28:11Speaker 01

  What we do, and we have been doing for a few years now, is that we will map patients that are being treated with an immunotherapy or a combination of immunotherapies and chemotherapies, and we're going to try and find separators between responders and non-responders. And the interesting thing is that when we do our immune profiling of patients, pre and post therapies, we see that some very subtle nuanced differences between responders and non-responders explain, or at least partially explain the reason. So we can find that a specific immune cell type and a specific gene within this immune cell type.

• 28:52Speaker 01

  Is correlated with no response to a therapy. So this can become a novel target for a novel therapeutics. And this is what we are doing. So the main point is to try and say, when you have one patient that is responding to a drug and another does not respond, it doesn't say much. But if you have 100 patients that respond and 100 patients that don't respond, you can start apply data science. And when you have the right data sets and the right technologies to measure the biology of the patients, you sometimes find very interesting patterns and explanations.

• 29:30Guy Raz?

  Okay. So if in fact, you could map the human immune system with incredible granularity at scale, and it sounds like you're on the path to doing that. Help me understand what that means for patients, for diseases, 20, 30, 40 years in the future. I mean, how does this impact how human disease is treated? I mean, realistically, could you imagine a world in even 50 years from now, where all cancers are treatable diseases, where people don't die from them?

• 30:04Speaker 01

  Yeah, so it's a very interesting question. And I'm going to say things not in the most accurate way, just to make sure that I can communicate the message. You take a patient with a cancer, let's say a solid tumor, and you take the biopsy of the tumor, or you dissect the tumor out, and you are going to do it in a dish, or maybe even give it to a mouse, and you will be able to cure the cancer outside the patient. And you're going to cure it by finding a new antibody or a new small molecule. But what you really want to know is what will happen within the patient.

• 30:43Speaker 01

  And the thing is that cancer, it's almost has its own intelligence. So there are different escape mechanisms and different ways that the cancer can use in order to survive or to grow. And the big question is, can we use this mapping of the human immune system?

• 31:06Speaker 01

  And use different animal models and different in vitro models, different lab models to try and predict what would have happened to the patient. So it's a combination of measuring cancer patients that have different types of cancers and apply a lot of computer aided simulations in order to predict what would have happened to a patient where they treated with this therapy. And this is the challenge. So the thing is that the human immune system and the cancer, they have this sort of battle. We are trying to understand how to help the human immune system win the battle.

• 31:50Speaker 01

  And it's a long, long, long road ahead.

• 31:54Guy Raz?

  We've got to take another quick break, but when we come back, more from Noam Solomon, co-founder and CEO of Immunai. I'm Guy Raz and you're listening to How I Built This Lab.

• 32:14Guy Raz?

  Welcome back to How I Built This Lab. I'm Guy Raz and my guest is Noam Solomon, whose company Immunai is using artificial intelligence to map the human immune system. So with your background in mathematics and computer science and your colleagues' background in biology, you're essentially tackling this challenge from multiple perspectives and obviously with an emphasis on AI and on just massive computer power.

• 32:42Speaker 01

  Right, so we have about 150 people that are between New York, San Francisco, Tel Aviv, Zurich and Prague that are spanning multiple disciplines. Immunology, medicine, technologies in single cell, machine learning, computational biology, software engineering, data engineering. And the secret is not to have those efforts done separately. The secret is to try to create multidisciplinary teams that are going to work together towards a common goal. And mathematicians such as myself are going to have to study a lot of immunology and biology in order to collaborate with their colleagues that come from biology and immunology.

• 33:27Speaker 01

  And similarly, immunologists are going to study the background they need in engineering or machine learning. And I believe that this is the new type of science that is more about connecting the dots between different disciplines and finding the bridges, which makes the challenge much harder, but so much more rewarding when you can figure out a way to use data science to answer a question in a different field. And as a mathematician and somebody that was never used to answer questions in biology, the satisfaction to be able to understand something that can explain why a certain patient may not respond well to a drug, and another patient that is very similar to

• 34:10Speaker 01

  this person will respond amazingly well to the drug is very fulfilling.

• 34:15Guy Raz?

  Noam, you wrote an article in a publication that I read, and I really love the piece. The title was something like "When Not Knowing is a Methodology." And you say that Immunai, not knowing, is a methodology, that essentially there's so much more that we don't know about the human immune system than we actually do, which I love. I love that idea, that essentially you don't really know, but that's the roadmap that you pursue. You follow this idea that we don't know, and let's figure it out.

• 34:49Speaker 01

  Right. So first of all, it's a personal methodology. I like to ask questions. I started the company. I didn't know anything about biology, medicine, business development, and I had to ask a lot of questions, and it became part of our culture as an organization. Because the company has such a bold vision, and we had to bring experts from many different disciplines, it became part of the way that we interact with one another, that asking questions is not only allowed, but is encouraged.

• 35:26Speaker 01

  In some places, you're expected to know the answer. I think for us, being able to ask the right questions really led us to make a lot of progress and became part of our, not only research culture, but also the way that we do business. I'm always open-minded collaborating with companies that are bringing something novel because maybe the union of the two approaches will be better. Maybe one plus one will be three. And yeah, sometimes you just don't know the answer, but you ask the right question, it will come out.

• 36:03Guy Raz?

  I read a piece by your co-founder, Luis, and he talked about when Google developed an AI program that can beat humans in the game Go, and the computer beat humans by using this counterintuitive move called Move37. I don't know the game well, but I read the article, and I guess the premise of the piece is that the move was so counterintuitive, so out of the box, that a human would never come up with that move on its own. I mean, when we're talking about the AI that you're using, could it eventually identify sort of a Move37-like approach that helps us cure cancer? I mean, is that what we're talking about?

• 36:39Speaker 01

  Yes, and I would say that what we are doing, this mapping of the human immune system, is much more higher dimensional than the problem that you just mentioned. I'll give an example. So, we are measuring from one patient, we're taking, let's say, we're drawing the blood. So, we would measure 10,000 cells. For each of the cell that we are going to map, we are going to measure 10,000 or 20,000 different genes, and proteins and other measurements. Now, we are doing this for, let's say, 1,000 patients. We are putting this information into a machine. This is not the equivalent of Go. No human being will have the intuition.

• 37:22Speaker 01

  To analyze all the relevant data. You have to use a machine to analyze the data. And I think this is where the movement or the the unique opportunity comes. There are certain types of problems where there is no human expertise to guide your ways. And until now, we have been only using, you know, a very, very small sliver of what is available. And so what to what Louis said, there are many counterintuitive things that humans would never come up when they develop or discover therapeutics. And I think a data driven way to mine a large data set is the way to go.

• 38:08Guy Raz?

  You know, there is this analogy between what you're doing and the work of developing autonomous vehicle technology. And with AVs, the data that they collect, right, is used to to make improvements to vehicles because it's it's collected from vehicle to vehicle and then the vehicles are automatically improved. And and the systems that govern them become improved with the increasing data. How is what you're doing similar to that? Is it the same principle essentially?

• 38:35Speaker 01

  So it is similar, but also more complicated. And maybe the similarity is exactly what what you just said. We are going to train our models on more and more data coming from clinical trials, measuring the accuracy of our algorithms. When we are wrong, we are going to recalibrate the models and do it again and again and again and improve the accuracy. But the place where this is really different is that for autonomous vehicles, you have experts. And every driver that can drive a car, you can ask whether an autonomous vehicle drives as good as a driver like me and you.

• 39:16Speaker 01

  For drug development, even the best scientists in the world, they don't know. As as we mentioned earlier, only 10% of drugs are going to succeed. And the question is, how can you build a machine that is not going to be as good as a scientist? It's going to be much, much, much better.

• 39:37Guy Raz?

  Noam, you mentioned this idea of risk and uncertainty with what you are working on and with the business that you've built. But it seems like where you are already, four-plus years in, is promising and that it seems to be on the right path. Why do you think that there is still so much risk involved with what you're trying to do?

• 40:00Speaker 01

  First of all, I think it's a good mindset. I think that when you understand that the risk is high, you are more likely to take steps that are going to be non-conformist and non-conformal, and you're going to think about the problem in a different way. What I'm trying to do with Immunine, what I'm trying to do with our board of directors, with our future investors, with our team, I want everybody to know that we are trying to do something extremely difficult, very unlikely to succeed. Not because internally I don't think we're going to make it. I think every year, every quarter, every month, we

• 40:44Speaker 01

  are making a lot of progress and I'm becoming increasingly more confident that this problem is solvable and we're going to make it. But the mindset of thinking big and taking risks is the mindset that I want to have when we are waking up in the morning, when we don't go to sleep late in the evening. And at least it's my mindset, and I think it's very productive.

• 41:05Guy Raz?

  That's Noam Solomon, co-founder and CEO of Immunine. Noam, thanks so much for being on the show.

• 41:12Speaker 01

  Thanks, Guy. Thanks for having me.

• 41:15Guy Raz?

  Hey, thanks so much for listening to How I Built This Lab. Please do follow us on your podcast app so you always have the latest episode downloaded. If you want to follow us on Twitter, our account is at HowIBuiltThis, and mine is at Guy Raz. And on Instagram, I'm at Guy.Raz. If you want to contact the team, our email address is [email protected].

• 41:39Guy Raz?

  This episode was produced by Sam Paulson and edited by John Isabella. Our music was composed by Rameet Aravulu. Our audio engineer was Neil Rouch. Our production team at How I Built This includes Alex Chung, Casey Herman, Chris Messini, Elaine Coats, J.C. Howard, Liz Metzger, Carla Estevez, and Kerry Thompson. Our intern is Susanna Brown. Neva Grant is our supervising editor. Beth Donovan is our executive producer. I'm Guy Raz, and you've been listening to How I Built This.